While some compounding pharmacies have stopped making alternatives to Wegovy and Zepbound since shortages were declared over, ...

A new drug is helping families who've spent years padlocking fridges, chaining garbage cans, and hiding food as their ...

Eli Lilly's experimental obesity drug, eloralintide, helped some patients lose 11.5% of their body weight at 12 weeks in an ...

A meta-analysis of 19 studies found that pediatric patients with hidradenitis suppurativa (HS) show an increased rate of ...

Obesity, diabetes and cardiovascular diseases are increasingly present in the population. Brown adipose tissue has a ...

Despite an increase in the prevalence of prescribing, only 0.5% of U.S. adolescents with obesity were prescribed an obesity ...

Starting July 7, 2025, the two highest doses of Zepbound will be available for a flat price of $499 per month, with shipments ...

Eli Lilly's drug, called eloralintide, helped some patients lose more than 11% of their body weight in three months.

An investigational drug developed by Eolo Pharma is showing promise in animal experiments and an early human trial. It could eventually be an alternative or add-on to popular GLP-1 medications.

Insulin changed the way we treat and manage diabetes. Chemotherapy has precipitously reduced the mortality rate of certain cancers. Now, GLP-1 medications are reshaping the way we treat obesity.